Automatic planning of the lower extremities for total marrow irradiation using volumetric modulated arc therapy.
Automation
Field junction
Radiotherapy
TMI
VMAT
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
29
07
2022
accepted:
25
09
2022
pubmed:
4
11
2022
medline:
25
3
2023
entrez:
3
11
2022
Statut:
ppublish
Résumé
Total marrow (and lymphoid) irradiation (TMI-TMLI) is limited by the couch travel range of modern linacs, which forces the treatment delivery to be split into two plans with opposite orientations: a head-first supine upper-body plan, and a feet-first supine lower extremities plan. A specific field junction is thus needed to obtain adequate target coverage in the overlap region of the two plans. In this study, an automatic procedure was developed for field junction creation and lower extremities plan optimization. Ten patients treated with TMI-TMLI at our institution were selected retrospectively. The planning of the lower extremities was performed automatically. Target volume parameters (CTV_J‑V The automatic procedure required 60-90 min, depending on the case. All automatic plans achieved clinically acceptable dosimetric results (CTV_J‑V The developed procedure allowed treatment planning of TMI-TMLI to be streamlined, increasing efficiency and standardization, preventing human errors, while maintaining the dosimetric plan quality and complexity of manual plans. Automated strategies can simplify the future adoption and clinical implementation of TMI-TMLI treatments in new centers.
Identifiants
pubmed: 36326856
doi: 10.1007/s00066-022-02014-0
pii: 10.1007/s00066-022-02014-0
pmc: PMC10033624
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
412-419Subventions
Organisme : Ministero della Salute
ID : GR-2019-12370739
Informations de copyright
© 2022. The Author(s).
Références
Med Phys. 2010 Feb;37(2):505-15
pubmed: 20229859
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1193-8
pubmed: 17967308
J Appl Clin Med Phys. 2021 Mar;22(3):119-130
pubmed: 33565214
Phys Med. 2019 Apr;60:162-167
pubmed: 31000078
J Appl Clin Med Phys. 2021 Oct;22(10):169-177
pubmed: 34480829
J Appl Clin Med Phys. 2012 Jan 05;13(1):3653
pubmed: 22231216
Cancers (Basel). 2021 Nov 11;13(22):
pubmed: 34830802
Transplant Cell Ther. 2021 Jun;27(6):492.e1-492.e6
pubmed: 33857448
J Clin Oncol. 2021 Feb 1;39(4):295-307
pubmed: 33332189
Cancer Radiother. 2017 Aug;21(5):365-372
pubmed: 28532617
Pract Radiat Oncol. 2021 Jan-Feb;11(1):e98-e105
pubmed: 32160952
Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):273-9
pubmed: 18786784
Strahlenther Onkol. 2021 Aug;197(8):722-729
pubmed: 33852037
Radiother Oncol. 2012 Feb;102(2):315-20
pubmed: 21724284
Lancet Oncol. 2020 Oct;21(10):e477-e487
pubmed: 33002443
Bone Marrow Transplant. 2003 Sep;32(6):543-8
pubmed: 12953124
Technol Cancer Res Treat. 2006 Oct;5(5):513-19
pubmed: 16981794
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):521-529
pubmed: 29893272
Pract Radiat Oncol. 2021 Sep-Oct;11(5):415-423
pubmed: 33711488
Phys Med. 2015 Nov;31(7):677-82
pubmed: 26068115
Med Phys. 2013 Nov;40(11):111713
pubmed: 24320421
Radiother Oncol. 2017 Aug;124(2):302-310
pubmed: 28687395
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):592-9
pubmed: 21345619
Med Phys. 2008 Dec;35(12):5609-18
pubmed: 19175118
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):628-36
pubmed: 21277109
Strahlenther Onkol. 2022 Jun;198(6):547-557
pubmed: 35318487
Med Dosim. 2012 Autumn;37(3):314-20
pubmed: 22326734
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1256-65
pubmed: 21035960
Nat Rev Clin Oncol. 2020 Dec;17(12):771-781
pubmed: 32843739
Med Phys. 2005 Oct;32(10):3214-24
pubmed: 16279075
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1259-67
pubmed: 17336225
Blood. 2001 Jun 1;97(11):3669-71
pubmed: 11392326